Applying the Partial Order Continual Reassessment Method to High‐Dimensional Treatment Combinations
Open Access
- 27 February 2026
- journal article
- Published by Wiley in Statistics in Medicine
- Vol. 45 (6-7)
Abstract
Recent years have seen increasing popularities in therapies that combines several drugs and/or schedules, which imposes great difficulties on the design of appropriate Phase I clinical trials. The Partial Ordering Continual Reassessment Method (POCRM), among others, is a popular design that can be easily adapted to those complex settings. However, the design is introduced and evaluated in the setting of the combination of two drugs, and the combination of more than two drugs has rarely been investigated. In particular, the specification of toxicity orderings has always been an essential part of the POCRM, which becomes more difficult in high‐dimensional settings due to the combinatorially increasing nature of the number of possible orderings of combination/schedules. This article proposes a systematic approach to specify orderings based on asymptotic properties in the setting of the combination of more than two drugs. Large simulation studies show that this novel ordering specification method leads to better design performance both asymptotically and with finite sample sizes.Keywords
Funding Information
- Gates Cambridge Trust
- National Institute for Health and Care Research (NIHR300576)
- Medical Research Council (MC UU 00002/19)
This publication has 20 references indexed in Scilit:
- Practical implementation of the partial ordering continual reassessment method in a Phase I combination‐schedule dose‐finding trialStatistics in Medicine, 2022
- Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trialsThe Lancet, 2022
- Consistency of the CRM when the dose‐toxicity curve is not monotone and its application to the POCRMStatistics in Medicine, 2021
- A benchmark for dose-finding studies with unknown orderingBiostatistics, 2021
- Keyboard design for phase I drug-combination trialsContemporary Clinical Trials, 2020
- A product of independent beta probabilities dose escalation design for dual‐agent phase I trialsStatistics in Medicine, 2015
- Phase I design for completely or partially ordered treatment schedulesStatistics in Medicine, 2013
- Specifications of a continual reassessment method design for phase I trials of combined drugsPharmaceutical Statistics, 2013
- Designs for Single‐ or Multiple‐Agent Phase I TrialsBiometrics, 2004
- Dose‐Finding with Two Agents in Phase I Oncology TrialsBiometrics, 2003